Morgan Stanley on Viking (VKTX): 'we view initiation of large Ph3 studies on schedule as an incremental positive'
Tweet Send to a Friend
Morgan Stanley analyst Michael E Ulz reiterated an Overweight rating and $102.00 price target on Viking Therapeutic (NASDAQ: VKTX).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
